Pharmaceuticals APAC News & Press Release Distribution

RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19

TEL AVIV, Israel and RALEIGH, NC, June 21, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral o...

2021-06-21 19:00 6962

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors

HONG KONG, June 21, 2021 /PRNewswire/ -- HUTCHMED (China) Limited ("HUTCHMED ") (Nasdaq/AIM: HCM) today announces that surufatinib has been granted approval for drug registration by the National Medical Products Administration ofChina ("NMPA") for the treatment of adv...

2021-06-21 15:15 3409

CStone announces first prescriptions of precision therapy GAVRETO® (pralsetinib) issued across China for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer after platinum-based chemotherapy

SUZHOU, China, June 21, 2021 /PRNewswire/ -- GAVRETO® (pralsetinib), a precision therapy discovered by CStone Pharmaceuticals' partner Blueprint Medicines, had the first batch of prescriptions issued at Guangdong Province People's Hospital and around 100 other hospitals acrossChina. GAVRETO is al...

2021-06-21 13:06 2592

Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology

SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...

2021-06-21 08:00 5020

Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology

CARsgen Therapeutics officially listing on HKEX

HONG KONG, June 19, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (the "Company", stock code: 2171.HK) today announced that the Company's Shares have been traded on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code "2171.HK".

2021-06-19 02:57 8637

CARsgen Therapeutics officially listing on HKEX

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

MELBOURNE, Australia, June 18, 2021 /PRNewswire/ -- New data released today shows thatAustralia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus. ...

2021-06-18 14:16 14206

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

MELBOURNE, Australia, June 18, 2021 /PRNewswire/ -- New data released today shows thatAustralia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus. ...

2021-06-18 14:04 14047

Gilead Sciences Announces Subanalyses of Safety and Efficacy Data from a Phase 2 Study of Chronic Hepatitis B Patients with Renal or Hepatic Impairment Switching to Vemlidy(r)

HONG KONG, June 18, 2021 /PRNewswire/ -- Gilead Sciences, Inc. today announced new sub-analysis data from a Phase 2 open-label study (GS-US-320-4035; NCT03180619), evaluating the safety and efficacy of switching to Vemlidy®# (tenofovir alafenamide 25 mg, TAF) from tenofovir disoproxil fumarate (T...

2021-06-18 10:00 2008

Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment

BEIJING and SHANGHAI and BOSTON, June 18, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has announced that the first two patients have been dosed in the Phase 1/2a clinical trial ofSHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respe...

2021-06-18 08:31 2833

Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion

SAN FRANCISCO and SUZHOU, China, June 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2021-06-18 08:00 2562

Envirotainer Announces Cathay Pacific as First Asian carrier for the recently released Releye® RLP container

STOCKHOLM, June 17, 2021 /PRNewswire/ -- Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, today announced that Cathay Pacific has approved the Envirotainer Releye® RLP for carriage on its fleet of aircraft. Cathay Pacific can now off...

2021-06-17 19:49 1318

Elekta radiotherapy system designed for changing cancer landscape now available for U.S. patients

ATLANTA, June 17, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that its Elekta Harmony* radiation therapy system recently received U.S. FDA 510(k) clearance, paving the way for U.S. clinics to harness the system to treat a comprehensive range of indications using the latest radiotherap...

2021-06-17 14:38 15076

Gannex Announces Positive Topline Results of the U.S. Phase I Trial of NASH Drug ASC42, an FXR Agonist

SHANGHAI, June 16, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces positive topline results of safety and pharmacodynamic ...

2021-06-16 21:00 2774

Galimedix Accelerating Development of Its Next-Generation Oral Anti-Amyloid Beta Drug GAL-201 for Alzheimer's Disease

Following recent FDA approval of Biogen's Alzheimer antibody drug ADUHELM (TM), targeting oligomers of amyloid beta, Galimedix aims for first patients with its GAL-201 oral small molecule drug within one year. KENSINGTON, Md., June 16, 2021 /PRNewswire/ -- Galimedix, Inc., a clinical-stage bioph...

2021-06-16 04:38 1012

Qynapse to present clinical results of QyScore® for Alzheimer's Disease and Multiple Sclerosis at the 7th Congress of the European Academy of Neurology

BOSTON, June 15, 2021 /PRNewswire/ -- QYNAPSE Inc., a medical technology company commercializing the most advanced artificial intelligence neuroimaging platform, today announced it will present clinical data on QyScore® for Alzheimer's disease and multiple sclerosis at the 7th Congress of the Eur...

2021-06-15 18:00 1952

Innovent Announces First Overweight or Obese Subject Dosed in A Phase 2 Clinical Trial of IBI362 (a GLP-1 and Glucagon Receptor Dual Agonist) in China

SAN FRANCISCO and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...

2021-06-15 12:00 3649

Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors

SUZHOU, China, and ROCKVILLE, Md., June 15, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Investigational Ne...

2021-06-15 07:39 16008

Viraleze registered for sale in Covid-ravaged India

MELBOURNE, Australia, June 11, 2021 /PRNewswire/ -- India's vast population will have access from today to the Australian developed anti-COVID nasal spray Viraleze™ following its registration in the country. The announcement...

2021-06-11 15:15 12838

Viraleze registered for sale in Covid-ravaged India

MELBOURNE, Australia, June 11, 2021 /PRNewswire/ -- India's vast population will have access from today to the Australian developed anti-COVID nasal spray Viraleze™ following its registration in the country. The announcement...

2021-06-11 15:03 1406

Long-lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2 (COVID-19 Virus)

OSAKA, Japan, June 11, 2021 /PRNewswire/ -- Taiko Pharmaceutical Co., Ltd. based inOsaka, Japan, hereby announced that long-lasting chlorine dioxide (ClO2) aqueous solution (*1) inactivated over 99.99% of SARS-CoV-2 (COVID-19 Virus), including its Alpha and Gamma variants (*2), in a test conducte...

2021-06-11 14:00 1804